Moving forward in clinical trials for ALS: motor neurons lead the way please

Drug Discov Today. 2014 Apr;19(4):441-9. doi: 10.1016/j.drudis.2013.10.014. Epub 2013 Oct 27.

Abstract

Amyotrophic lateral sclerosis (ALS) is one of the most complex motor neuron diseases. Even though scientific discoveries are accelerating with an unprecedented pace, to date more than 30 clinical trials have ended with failure and staggering frustration. There are too many compounds that increase life span in mice, but too little evidence that they will improve human condition. Increasing the chances of success for future clinical trials requires advancement of preclinical tests. Recent developments, which enable the visualization of diseased motor neurons, have the potential to bring novel insight. As we change our focus from mice to motor neurons, it is possible to foster a new vision that translates into effective and long-term treatment strategies in ALS and related motor neuron disorders (MND).

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Amyotrophic Lateral Sclerosis / metabolism
  • Amyotrophic Lateral Sclerosis / physiopathology*
  • Animals
  • Clinical Trials as Topic
  • Glutamic Acid / metabolism
  • Humans
  • Mitochondria / physiology
  • Motor Neurons / physiology*
  • Nerve Growth Factors / physiology

Substances

  • Nerve Growth Factors
  • Glutamic Acid